Ganti Apar Kishor, Mulshine James L
Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, Nebraska 68198-7680, USA.
Oncologist. 2006 May;11(5):481-7. doi: 10.1634/theoncologist.11-5-481.
Advances in imaging technology have ushered in a new era for lung cancer screening in high-risk individuals using computed tomographic (CT) scans. Although most published studies are nonrandomized observational cohorts of volunteers, the ability of CT scans to detect early stage lung cancer is undisputable. What is unresolved is the ability of spiral CT screening to affect lung cancer-related mortality. A large randomized trial sponsored by the National Cancer Institute to address this question is currently under way. Genomic and proteomic approaches promise to complement the ability of spiral CT to detect early lung cancer in the next few years. Currently, the decision to screen for lung cancer should involve a careful discussion with the individuals involved about the potential advantages, costs, and drawbacks of the approach.
成像技术的进步开启了一个新时代，即使用计算机断层扫描（CT）对高危个体进行肺癌筛查。尽管大多数已发表的研究都是志愿者的非随机观察队列，但CT扫描检测早期肺癌的能力是无可争议的。尚未解决的问题是螺旋CT筛查对肺癌相关死亡率的影响。美国国立癌症研究所赞助的一项大型随机试验正在进行中，以解决这个问题。基因组学和蛋白质组学方法有望在未来几年补充螺旋CT检测早期肺癌的能力。目前，肺癌筛查的决定应该与相关个体仔细讨论这种方法的潜在优势、成本和缺点。
